Thursday, 5 November 2026European Markets

AIRTHINGS Stock Impressive Rise 13% So Far On Monday, Outperforms Market

Loading stream...

(VIANEWS) - Shares of AIRTHINGS (Oslo Børs Benchmark Index_GI: AIRX.OL) jumped by a staggering 13.62% to kr2.92 at 11:23 EST on Monday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is sliding 0.29% to kr1,215.57, after three successive sessions in a row of losses. This seems, so far, a somewhat negative trend exchanging session today.

AIRTHINGS's last close was kr2.92, 49.13% under its 52-week high of kr5.74.

About AIRTHINGS

Airthings ASA, a hardware-enabled software company, develop products and systems for monitoring indoor air quality, radon, and energy efficiency worldwide. It operates through Consumer, Business, and Professional segments. The Consumer segments sells air quality sensors to private customers through retail and e-commerce. Its Business segment provides air quality solutions to schools, office building, and other commercial buildings. The Professional segment sells measurement solutions, which enables inspectors and certified radon professionals to measure, analyze, and report on buildings; and offers rental of products and calibration services. In addition, it offers digital radon detectors as well as smart indoor air quality monitors and solutions. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. Airthings ASA was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, AIRTHINGS has a trailing twelve months EPS of kr-0.52.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -16.08%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AIRTHINGS's stock is considered to be oversold (<=20).

More news about AIRTHINGS (AIRX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com